ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 102 filers reported holding ASCENDIS PHARMA A/S in Q2 2018. The put-call ratio across all filers is 1.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,580,758 | +163.4% | 112,994 | +151.1% | 0.07% | +140.0% |
| Q2 2023 | $4,016,250 | -16.8% | 45,000 | 0.0% | 0.03% | -28.6% |
| Q1 2023 | $4,824,900 | +7.2% | 45,000 | +15.1% | 0.04% | -27.6% |
| Q2 2019 | $4,502,000 | -31.5% | 39,101 | -30.0% | 0.06% | -33.3% |
| Q1 2019 | $6,577,000 | +930.9% | 55,878 | +520.9% | 0.09% | +1142.9% |
| Q3 2018 | $638,000 | -74.2% | 9,000 | -75.8% | 0.01% | -68.2% |
| Q2 2018 | $2,474,000 | +41.7% | 37,190 | +39.3% | 0.02% | +57.1% |
| Q1 2018 | $1,746,000 | -49.6% | 26,700 | -69.1% | 0.01% | -50.0% |
| Q4 2017 | $3,465,000 | -13.1% | 86,500 | -21.4% | 0.03% | -6.7% |
| Q3 2017 | $3,988,000 | +236.0% | 110,000 | +64.0% | 0.03% | +114.3% |
| Q3 2015 | $1,187,000 | -44.9% | 67,079 | -45.0% | 0.01% | +16.7% |
| Q2 2015 | $2,154,000 | +24.2% | 121,880 | +21.9% | 0.01% | -50.0% |
| Q1 2015 | $1,734,000 | – | 99,955 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |